Modern Retina Newsletter

To view this email as a web page, click here.

OCTA may be harbinger for anti-VEGF efficacy

When used one week after injection, optical coherence tomography angiography can help clinicians determine how effective their treatment has been on neovascular membrane reperfusion, according to Paul Tornambe, MD.

Continue

Light induced visual-response: Objective, functional vision testing

Light induced visual-response (LIV)—the use of light to stimulate electrical responses from cells within the eye—has recently emerged as a better way to describe visual electrophysiology testing. Modern LIV tests can help guide clinical decision making in pathologies that we see on a routine basis by using streamlined protocols and platforms, says Steven M. Silverstein, MD, FACS.

Find out

Achromatopsia: Understanding the rare inherited retinal disease

A recent global survey shows achromatopsia remains relatively misunderstood and underdiagnosed, and individuals with this disease face a difficult journey in pursuit of an early and accurate diagnosis, reports Christine N. Kay, MD.

Diabetic eye disease advances, but questions remain

Anti-VEGFs can improve DRSS in majority of patients

What retinal specialists should know about their pregnant patients

What to know about this rare inherited retinal disease

How about a complimentary dinner program, plus invigorating discussion with experts and peers about Wet AMD and DME? Chicago, Saturday, October 27, 2018 brought to you by Ophthalmology Times and Regeneron.

Save your seat now. »

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.